PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07K 14/685, C12N 15/16, A61K 38/34 | A1

(11) International Publication Number: WO 99/57148

(43) International Publication Date: 11 November 1999 (11.11.99)

(21) International Application Number: PCT/GB99/01388

(22) International Filing Date: 5 May 1999 (05.05.99)

(30) Priority Data:
9801571-2 5 May 1998 (05.05.98) SE

(71) Applicant *(for all designated States except US)*: WA PHARM AB [SE/SE]; c/o Melacure Therapeutics AB, Uppsala Science Park, S-751 83 Uppsala (SE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: SZARDENINGS, Michael [DE/DE]; Öselweg 20, D-38302 Wolfenbüttel (DE). MUCENIECE, Ruta [LV/SE]; Semanders väg 3, S-752 61 Uppsala (SE). MUTULE, Ilze [LV/SE]; Bellmansgatan 36, S-754 26 Uppsala (SE). MUTULIS, Felikss [LV/SE]; Bellmansgatan 36, S-754 26 Uppsala (SE). WIKBERG, Jarl [SE/SE]; Stora Malmgatan 9, S-193 35 Sigtuna (SE).

(74) Agent: PETT, Christopher, Phineas; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4 4EL (GB).

(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: MELANOCORTIN 1 RECEPTOR SELECTIVE COMPOUNDS



(1)

(57) Abstract

A compound of general formula (1) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are H or methyl, R13, R14, R15 and R16 are H or alkyl, wherein L1 and L2 are linkers selected from single bond, methyl, ethyl, wherein R19, R20 and R21 are H or $-CH_2X$, NT is selected from H, hydroxyl, alkyl, aminoacid, aminoacid analogue, polypeptide and functional group, CT is selected from hydrogen, hydroxyl, alkyl, aminoacid, aminoacid analogue, polypeptide and functional group shows high selectivity and high affinity for MC1-receptors in combination with effective stimulation or inhibiton of cAMP formation in MC1-receptor expressing cells but low affinity for other subtypes of MC-receptors and may be used to treat a wide range of inflammatory conditions. Also disclosed is a DNA molecule and a corresponding vector encoding the compound, a fusion protein comprising a copy of it, a vector comprising DNA encoding the fusion protein, and a pharmaceutical composition comprising the compound.